Niclosamide enhances ROS-mediated cell death through c-Jun activation

Biomedicine and Pharmacotherapy

Volumn 68, Issue 5, 2014, Pages 619-624

  Lee, Sae lo oom ^a   Son, A Rang ^a,b   Ahn, Jiyeon ^a   Song, Jie Young ^a  

^a Korea Institute of Radiation and Medical Science   (South Korea)

^b Hanyang University   (South Korea)

Author keywords

Apoptosis; C Jun; Drug repositioning; Niclosamide; P38 MAPK; Radiosensitizer; Radiotherapy

Indexed keywords

ACETYLCYSTEINE; HYDROGEN PEROXIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; NICLOSAMIDE; PROTEIN C JUN; RADIOSENSITIZING AGENT; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CELL DEATH; CELL VIABILITY ASSAY; CYTOTOXICITY; DOSE RESPONSE; GAMMA RADIATION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LUNG CANCER CELL LINE; LUNG NON SMALL CELL CANCER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; CHEMISTRY; DRUG EFFECTS; GENE SILENCING; IONIZING RADIATION; METABOLISM; PHOSPHORYLATION; RADIATION RESPONSE; RADIATION TOLERANCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL DEATH; CELL LINE, TUMOR; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYDROGEN PEROXIDE; NICLOSAMIDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-JUN; RADIATION TOLERANCE; RADIATION, IONIZING; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84905102301     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.03.018     Document Type: Article

References (25)

1. Biddlestone-Thorpe L., Sajjad M., Rosenberg E., Beckta J.M., Valerie N.C., Tokarz M., et al. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin Cancer Res 2013, 19:3189-3200.
2. Lee S., Lim M.J., Kim M.H., Yu C.H., Yun Y.S., Ahn J., et al. An effective strategy for increasing the radiosensitivity of human lung cancer cells by blocking Nrf2-dependent antioxidant responses. Free Radic Biol Med 2012, 53:807-816.
3. Lally B.E., Geiger G.A., Kridel S., Arcury-Quandt A.E., Robbins M.E., Kock N.D., et al. Identification and biological evaluation of a novel and potent small molecule radiation sensitizer via an unbiased screen of a chemical library. Cancer Res 2007, 67:8791-8799.
4. Lee Y.Y., Park W., Huh S.J., Yoon A., Park J.Y., Choi C.H., et al. Platinum-based combination chemotherapy vs. weekly cisplatin during adjuvant CCRT in early cervical cancer with pelvic LN metastasis. Anticancer Res 2013, 33:4675-4681.
5. Otto K.B., Acharya S.S., Robinson V.L. Stress-activated kinase pathway alteration is a frequent event in bladder cancer. Urol Oncol 2012, 30:415-420.
6. Estus S., Zaks W.J., Freeman R.S., Gruda M., Bravo R., Johnson E.M. Altered gene expression in neurons during programmed cell death: identification of c-jun as necessary for neuronal apoptosis. J Cell Biol 1994, 127:1717-1727.
7. Ham J., Babij C., Whitfield J., Pfarr C.M., Lallemand D., Yaniv M., et al. A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron 1995, 14:927-939.
8. Whitfield J., Neame S.J., Paquet L., Bernard O., Ham J. Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron 2001, 29:629-643.
9. Watson A., Eilers A., Lallemand D., Kyriakis J., Rubin L.L., Ham J. Phosphorylation of c-Jun is necessary for apoptosis induced by survival signal withdrawal in cerebellar granule neurons. J Neurosci 1998, 18:751-762.
10. Madeo A., Vinciguerra M., Lappano R., Galgani M., Gasperi-Campani A., Maggiolini M., et al. c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells. Oncogene 2010, 29:978-991.
11. Vinciguerra M., Esposito I., Salzano S., Madeo A., Nagel G., Maggiolini M., et al. Negative charged threonine 95 of c-Jun is essential for c-Jun N-terminal kinase-dependent phosphorylation of threonine 91/93 and stress-induced c-Jun biological activity. Int J Biochem Cell Biol 2008, 40:307-316.
12. Lu W., Lin C., Roberts M.J., Waud W.R., Piazza G.A., Li Y. Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt/beta-catenin pathway. PLoS One 2011, 6:e29290.
13. Sack U., Walther W., Scudiero D., Selby M., Kobelt D., Lemm M., et al. Novel effect of antihelminthic Niclosamide on S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst 2011, 103:1018-1036.
14. Balgi A.D., Fonseca B.D., Donohue E., Tsang T.C., Lajoie P., Proud C.G., et al. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling. PLoS One 2009, 4:e7124.
15. Jin Y., Lu Z., Ding K., Li J., Du X., Chen C., et al. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species. Cancer Res 2010, 70:2516-2527.
16. Tan X.L., Ren X.G., Chen Y.G. [Correlation between myocardial injury induced by acute carbon monoxide poisoning and NT proBNP]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2010, 28:454-455.
17. Organization WH WHO Specifications and Evaluations for Public Health Pesticides (niclosamide) 2002, 1-24. World Health Organization, Geneva.
18. Osada T., Chen M., Yang X.Y., Spasojevic I., Vandeusen J.B., Hsu D., et al. Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations. Cancer Res 2011, 71:4172-4182.
19. Yo Y.T., Lin Y.W., Wang Y.C., Balch C., Huang R.L., Chan M.W., et al. Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther 2012, 11:1703-1712.
20. Park S.J., Shin J.H., Kang H., Hwang J.J., Cho D.H. Niclosamide induces mitochondria fragmentation and promotes both apoptotic and autophagic cell death. BMB Rep 2011, 44:517-522.
21. Humar M., Loop T., Schmidt R., Hoetzel A., Roesslein M., Andriopoulos N., et al. The mitogen-activated protein kinase p38 regulates activator protein 1 by direct phosphorylation of c-Jun. Int J Biochem Cell Biol 2007, 39:2278-2288.
22. Birkenkamp K.U., Tuyt L.M., Lummen C., Wierenga A.T., Kruijer W., Vellenga E. The p38 MAP kinase inhibitor SB203580 enhances nuclear factor-kappa B transcriptional activity by a non-specific effect upon the ERK pathway. Br J Pharmacol 2000, 131:99-107.
23. Muniyappa H., Das K.C. Activation of c-Jun N-terminal kinase (JNK) by widely used specific p38 MAPK inhibitors SB202190 and SB203580: a MLK-3-MKK7-dependent mechanism. Cell Signal 2008, 20:675-683.
24. Morton S., Davis R.J., McLaren A., Cohen P. A reinvestigation of the multisite phosphorylation of the transcription factor c-Jun. EMBO J 2003, 22:3876-3886.
25. Wisdom R., Johnson R.S., Moore C. c-Jun regulates cell cycle progression and apoptosis by distinct mechanisms. EMBO J 1999, 18:188-197.